Test Menu

Biocept’s Target Selector™ platform features a range of liquid biopsy tests to assess NCCN guideline-driven-clinically actionable cancer biomarkers from a patient’s blood sample.

Increasing Access to Targeted Therapies via Liquid Biopsy
Test Technology Result Interpretation CPT Codes Method Targeted Therapies
ALK FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©, Alunbrig©
AR Expression Expression 88346 or 88350 CTC Zytiga©, Xtandi©
BRAF Sequencing Mutation 81210 ctDNA Zelboraf©, Tafinlar©, Mekinist©
CTC Antibody
Capture
Enumeration 86152/86153 88346x1, 88350x2 CTC
EGFR
T790M,DEL19,L858R
Sequencing Mutation 81235 ctDNA Tarceva©, Gilotrif©, Iressa©, Tagrisso©
ER Expression Expression 88346 or 88350 CTC Nolvadex©, Aromatase Inhibitors
FGFR1 FISH Amplification 88377 CTC Nolvadex©, Faslodex©, Femara©, Arimidex©, Aromasin©
HER2 FISH Amplification 88377 CTC Herceptin©, Perjeta©, Tykerb©, Kadcyla©
KRAS Sequencing Mutation 81275 ctDNA Erbitux©, Vectibix©
MET FISH Amplification 88377 CTC Xalkori©, Cabometyx©, Exelixi©, Tivantinib©
NRAS Sequencing Mutation 81311 ctDNA Erbitux©, Vectibix©
PD-L1 Expression Expression 88346 or 88350 CTC Keytruda©, Opdivo©
PR Expression Expression 88346 or 88350 CTC Nolvadex©, Aromatase Inhibitors
RET FISH Translocation 88377 CTC Cabometyx©, Capresla©
ROS1 FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©

ALP gene rearrangements are found In 2-7,6 of non-small cell lung cancer MISC.) CaSeS,MM detection is…qualify patients f or possible therapeutic intervention. In these rearrangement.me anaplastic lymphoma kinase 1.1.0 gene iS fUS’0 the echinoderm rnicrotubule-associated protein like been reported: all involve thesame cytoplasmic portion 01’1.AL,, prate,. but with d.rent truncations of EMU, Importantly,ALK rearrangements most commonly occur in the absence of EGF0. or PPAS mutations.’
ALK gene rearrangements, the resulting fusion proteins,may be detected in tumor specimensusIng fluorescence in sittS, hybridaatlon(FISH.leMsamslsMeaemestry 111-1C), or reverse transcription polymerase ca. reaction (lif-PC12).s Bloceptis Target Selects, Mule mopsymatsorm Pas the ability Co’ dentify ALK gene translocations in patients using a simple blots, sample.
Detection of an ALK fusion Pa. to determine use manhood as response to crizminie Osaikarisal or semi. (zykaelasaawa commerclany available tyrosine muse innieltors.3meicionaiiy,mecunib Wecensac) and boo.. (Alunerigo)are appnivee for patients with ALP-positive metastatic eisc. who Pave progressed war are Intolerant to
Targeted Therapies: Cr… Ptalkor113),serltInlb (Zykadla0), memunle Weems.), and bagatelle lmunPrissal.
MeMoslobg, Blocepfs ALK lip.blopsytest Is performed on circUating tumor cells (CSCs), using FISH analysistoidentjfy elapses rearrangements.

Order a Test
Requisition Form

partner with biocept

Contact us to learn how Biocept can support your research and testing.

1.888.332.7729

Test Menu

Biocept’s Target Selector™ platform features a range of liquid biopsy tests to assess NCCN guideline-driven-clinically actionable cancer biomarkers from a patient’s blood sample.

Increasing Access to Targeted Therapies via Liquid Biopsy
Test Technology Result Interpretation CPT Codes Method Targeted Therapies
ALK FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©, Alunbrig©
AR FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©, Alunbrig©
ALK FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©, Alunbrig©
ALK FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©, Alunbrig©
ALK FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©, Alunbrig©
ALK FISH Translocation 88377 CTC Xalkori©, Zykadia©, Alecensa©, Alunbrig©

ALP gene rearrangements are found In 2-7,6 of non-small cell lung cancer MISC.) CaSeS,MM detection is…qualify patients f or possible therapeutic intervention. In these rearrangement.me anaplastic lymphoma kinase 1.1.0 gene iS fUS’0 the echinoderm rnicrotubule-associated protein like been reported: all involve thesame cytoplasmic portion 01’1.AL,, prate,. but with d.rent truncations of EMU, Importantly,ALK rearrangements most commonly occur in the absence of EGF0. or PPAS mutations.’
ALK gene rearrangements, the resulting fusion proteins,may be detected in tumor specimensusIng fluorescence in sittS, hybridaatlon(FISH.leMsamslsMeaemestry 111-1C), or reverse transcription polymerase ca. reaction (lif-PC12).s Bloceptis Target Selects, Mule mopsymatsorm Pas the ability Co’ dentify ALK gene translocations in patients using a simple blots, sample.
Detection of an ALK fusion Pa. to determine use manhood as response to crizminie Osaikarisal or semi. (zykaelasaawa commerclany available tyrosine muse innieltors.3meicionaiiy,mecunib Wecensac) and boo.. (Alunerigo)are appnivee for patients with ALP-positive metastatic eisc. who Pave progressed war are Intolerant to
Targeted Therapies: Cr… Ptalkor113),serltInlb (Zykadla0), memunle Weems.), and bagatelle lmunPrissal.
MeMoslobg, Blocepfs ALK lip.blopsytest Is performed on circUating tumor cells (CSCs), using FISH analysistoidentjfy elapses rearrangements.

Order a Test
Requisition Form

partner with biocept

Contact us to learn how Biocept can support your research and testing.

1.888.332.7729